Should Patients at High Risk of Peritoneal Dissemination from Gastric and Colon cancers Undergo HIPEC as an Adjuvant Therapy? (SurgOnc Today 2021)

Activity Description

In this episode, Dr. Edward Levine, Vice Chair of the SSO Peritoneal Surface Malignancy DSWG, is joined by Dr. Brian Badgwell of MD Anderson Cancer Center and Dr. Pieter Tanis of the University of Amsterdam. They discuss whether patients at high risk of peritoneal dissemination from gastric and colon cancers should undergo HIPEC as an adjuvant therapy.

Summary


Availability:	On-Demand


Cost:	FREE


Credit Offered:	No Credit Offered